Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

Immune–microbiota interactions affect the prognosis of patients with colon cancer

We characterized cancer cells, immune responses and the microbiota composition in a cohort of primary colon cancers. Multi-omic analyses defined parameters associated with favorable prognosis, including a score that captured the intratumoral immune response and a specific microbiome signature. This data repository (atlas and compass of immune–cancer–microbiome interactions (AC-ICAM)) is publicly available.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: AC-ICAM interactions conducive to prolonged survival in patients with colon cancer.

References

  1. Giannakis, M. et al. Genomic correlates of Immune-cell infiltrates in colorectal carcinoma. Cell Rep. 15, 857–865 (2016). This paper reports associations between MSI, neoantigen loads, lymphocyte infiltration and clinical outcome in colorectal cancer.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Pagès, F. et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391, 2128–2139 (2018). Validation of the prognostic role of the ‘immunoscore’ in a large multi-centric cohort of patients with colon cancer.

    Article  PubMed  Google Scholar 

  3. Smith, M. et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat. Med. 28, 713–723 (2022). This article reports an association between gut microbiome and response or toxicity to CAR T cell therapy.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Roelands, J. et al. Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. J. Immunother. Cancer 8, e000617 (2020). This paper describes the prognostic role of the ICR across different tumor types.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Angelova, M. et al. Evolution of metastases in space and time under immune selection. Cell 175, 751–765 (2018). This paper proposes a parallel selection model of metastatic progression based on immune-editing mechanisms.

    Article  CAS  PubMed  Google Scholar 

  6. Messaoudene, M. et al. A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota. Cancer Discov. 12, 1070–1087 (2022). This paper reports that castalagin, an ellagitannin polyphenol, binds to R. bromii and promotes anti-tumor immune responses.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Roelands, J. et al. An integrated tumor, immune and microbiome atlas of colon cancer. Nat. Med. https://doi.org/10.1038/s41591-023-02324-5 (2023).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Immune–microbiota interactions affect the prognosis of patients with colon cancer. Nat Med 29, 1076–1077 (2023). https://doi.org/10.1038/s41591-023-02384-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02384-7

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer